Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resi...

Full description

Bibliographic Details
Main Authors: Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I. Harrell, Giada V. Zapparoli, Alison Hadley, Robert Holian, Emma Boehm, Valerie Heong, Elaine Sanij, Richard B. Pearson, John J. Krais, Neil Johnson, Orla McNally, Sumitra Ananda, Kathryn Alsop, Karla J. Hutt, Scott H. Kaufmann, Kevin K. Lin, Thomas C. Harding, Nadia Traficante, Australian Ovarian Cancer Study (AOCS), Anna deFazio, Iain A. McNeish, David D. Bowtell, Elizabeth M. Swisher, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott
Format: Article
Language:English
Published: Nature Publishing Group 2018-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-05564-z

Internet

https://doi.org/10.1038/s41467-018-05564-z

Similar Items